Published in Hum Gene Ther Methods on August 01, 2015
Ebola virus disease candidate vaccines under evaluation in clinical trials. Expert Rev Vaccines (2016) 0.82
B lymphocytes as direct antigen-presenting cells for anti-tumor DNA vaccines. Oncotarget (2016) 0.75
Mini-intronic plasmid vaccination elicits tolerant LAG3(+) CD8(+) T cells and inferior antitumor responses. Oncoimmunology (2016) 0.75
MyD88/CD40 Genetic Adjuvant Function in Cutaneous Atypical Antigen-Presenting Cells Contributes to DNA Vaccine Immunogenicity. PLoS One (2016) 0.75
Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage. J Virol (1998) 2.82
Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J Immunol (2000) 2.54
Electroporation delivery of DNA vaccines: prospects for success. Curr Opin Immunol (2011) 2.25
Transient electropermeabilization of cells in culture. Increase of the cytotoxicity of anticancer drugs. Biochem Pharmacol (1988) 1.91
Intradermal/subcutaneous immunization by electroporation improves plasmid vaccine delivery and potency in pigs and rhesus macaques. Vaccine (2007) 1.88
Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. Sci Transl Med (2012) 1.84
Electroporation of synthetic DNA antigens offers protection in nonhuman primates challenged with highly pathogenic avian influenza virus. J Virol (2009) 1.77
Enhancement of DNA vaccine potency in rhesus macaques by electroporation. Vaccine (2004) 1.74
Electropermeabilization of skeletal muscle enhances gene transfer in vivo. Gene Ther (1999) 1.74
In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers. PLoS One (2011) 1.71
Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery. J Infect Dis (2013) 1.63
DNA vaccines. Life Sci (1997) 1.53
Skin electroporation: effects on transgene expression, DNA persistence and local tissue environment. PLoS One (2009) 1.46
Prototype development and preclinical immunogenicity analysis of a novel minimally invasive electroporation device. Gene Ther (2010) 1.35
Enhancement of cellular immune response to a prostate cancer DNA vaccine by intradermal electroporation. Mol Ther (2005) 1.29
Multivalent smallpox DNA vaccine delivered by intradermal electroporation drives protective immunity in nonhuman primates against lethal monkeypox challenge. J Infect Dis (2011) 1.25
Potent immunogenicity of an HIV-1 gag-pol fusion DNA vaccine delivered by in vivo electroporation. Vaccine (2005) 1.19
Optimization of cutaneous electrically mediated plasmid DNA delivery using novel electrode. Gene Ther (2006) 1.17
Biochemistry of human skin--our brain on the outside. Chem Soc Rev (2005) 1.16
Optimization of skin electroporation in mice to increase tolerability of DNA vaccine delivery to patients. Mol Ther (2009) 1.15
Selected approaches for increasing HIV DNA vaccine immunogenicity in vivo. Curr Opin Virol (2011) 1.12
Dendritic cells: biology of the skin. Contact Dermatitis (2009) 1.11
DNA vaccines: crossing a line in the sand. Introduction to special issue. Vaccine (2008) 1.06
Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors. J Transl Med (2013) 1.05
DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8(+) T-cell responses and increases PSA doubling time. Cancer Immunol Immunother (2012) 1.02
Plasmid-based gene therapy of diabetes mellitus. Gene Ther (2007) 1.02
Microneedle delivery of H5N1 influenza virus-like particles to the skin induces long-lasting B- and T-cell responses in mice. Clin Vaccine Immunol (2010) 1.01
Direct and indirect control of T-cell activation by keratinocytes. J Invest Dermatol (1995) 0.98
Persistent immune responses induced by a human immunodeficiency virus DNA vaccine delivered in association with electroporation in the skin of nonhuman primates. Hum Gene Ther (2009) 0.97
A DNA-based candidate HIV vaccine delivered via in vivo electroporation induces CD4 responses toward the α4β7-binding V2 loop of HIV gp120 in healthy volunteers. Clin Vaccine Immunol (2012) 0.93
Gene expression and immune response kinetics using electroporation-mediated DNA delivery to muscle. J Gene Med (2005) 0.93
Elucidating the Kinetics of Expression and Immune Cell Infiltration Resulting from Plasmid Gene Delivery Enhanced by Surface Dermal Electroporation. Vaccines (Basel) (2013) 0.93
Safety and tolerability of the Easy Vax™ clinical epidermal electroporation system in healthy adults. Mol Ther (2011) 0.92
Optimization of electroporation-enhanced intradermal delivery of DNA vaccine using a minimally invasive surface device. Hum Gene Ther Methods (2012) 0.90
Immunogenicity of a novel engineered HIV-1 clade C synthetic consensus-based envelope DNA vaccine. Vaccine (2011) 0.90
Tolerability of intramuscular and intradermal delivery by CELLECTRA(®) adaptive constant current electroporation device in healthy volunteers. Hum Vaccin Immunother (2013) 0.84
DNA vaccination strategy targets epidermal dendritic cells, initiating their migration and induction of a host immune response. Mol Ther Methods Clin Dev (2014) 0.79
The basis of electrochemotherapy. Methods Mol Med (2000) 0.78